We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




FIT Hemoglobin Predicts Risk of Advanced Neoplasia

By LabMedica International staff writers
Posted on 09 Nov 2017
Colorectal cancer (CRC) screening using quantitative fecal immunochemical tests (FITs) is rapidly gaining ground worldwide and FITs are invariably used in a dichotomous manner using pre-specified cut-off values.

Hemoglobin (Hb) concentration in fecal immunochemical test (FIT) results during the first round of colorectal cancer (CRC) screening is an independent predictor of risk of advanced neoplasia (AN) and might be used in designing personalized strategies for CRC screening while reducing unnecessary repeat tests.

Gastroenterologists at the Erasmus MC University Medical Centre (Rotterdam, The Netherlands) analyzed data collected from a population-based study of 9,561 average-risk subjects (50-74 years old) in the Netherlands who were offered four rounds of FIT screening for CRC from November 2006 through December 2014. More...
They analyzed data from 7,663 participants screened at least once and found to have a negative FIT result at baseline (below the cut-off value of 10 μg Hb/ gram of feces [G]). Participants were followed for a median of 4.7 years (interquartile range, 2.0-6.1 years).

The investigators found that participants with two consecutive FIT Hb concentrations equal to or greater than 8 µg/G had a 14-fold increased risk of AN compared to those with baseline concentrations of 0 µg/G. Multi-variate hazard ratios increased from 1.2 for participants with FIT Hb concentrations 0–2 µg/G to 8.2 for those with concentrations 8–10 µg/G. This rising cumulative incidence of AN based on elevated FIT Hb levels was more prominent for Hb concentrations between 4 µg/G and 10 µg/G.

The authors concluded that in a population-based study of average-risk individuals with a FIT result below the cut-off value,they associated baseline concentrations of 8-10 μg fecal Hb/G with an increased risk of AN compared with baseline concentrations of 0 μg fecal Hb/G. Baseline and consecutive fecal Hb concentrations are independent predictors for incident AN. This information might be used in designing personalized strategies for population-based CRC screening and reduce unnecessary repeat tests. The study was originally published on July 28, 2017, in the journal Gastroenterology.

Related Links:
Erasmus MC University Medical Centre


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology System
Medonic M16C
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.